Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Metsä Board Corporation’s directed share issue without consideration for the payment of the rewards under the share plan for the restriction period 2022–2024

Metsä Board Corporation Stock exchange release Changes in company’s own shares 24 October 2024 9.05 a.m. EETThe Board of Directors of Metsä Board Corporation ("the Company") has today decided on a directed share issue without consideration for the payment of the rewards under the Company’s long-term restricted share plan 2020-2024 (restriction period 2022-2024) based on the authorisation to the Board of Directors granted by the Annual General Meeting on 26 March 2024. In the share issue, 11,394 series B shares held by the Company will be issued in deviation from shareholders' pre-emptive

Attendo to buy back shares for a maximum amount of SEK 150 million

Attendo’s Board of Directors has decided to utilize the authorization by the 2024 AGM to acquire own shares in order to adjust the company’s capital structure.The share buyback programme will be carried out in accordance with the EU Market Abuse Regulation (MAR) and Commission Delegated Regulation (EU) 2016/1052 (the so-called Safe Harbour Regulation). Acquisitions of shares will be managed by Skandinaviska Enskilda Banken AB.   The share buyback programme is subject to the following terms:   · Buybacks are to take place on Nasdaq Stockholm in accordance with its Rule Book for

ArcticZymes Highlights Industry-Leading Success at ESGCT 2024

Rome, Italy – October 24, 2024 – ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference.The annual ESGCT conference is renowned for spotlighting breakthrough innovations in gene and cell therapy. It acts as a global stage for companies to showcase the latest scientific and technological achievements impacting their work in the biotherapeutics industry.   In this context, ArcticZymes salt active nucleases

Quarterly Update – September 2024

24 October 2024 Ashoka WhiteOak Emerging Markets Trust plc (the "Company") Quarterly Update – September 2024 The Company's quarterly factsheet as at 30 September 2024 is now available: https://awemtrust.com/factsheet/ The Company NAV increased 1.75% in Q3 2024, underperforming the benchmark by 0.71%. The key contributors include Alibaba Group Holding (+47.8%), Hong Kong Exchanges (+25.8%) and Prosus (+15.8%), whereas Samsung Electronics (-24.7%), SK hynix (-26.8%) and ASML Holding (-24.0%) were the key detractors.   Market Review   In 3Q 2024, the MSCI EM index

Structural change in the Riikku Group

Balco Group is constantly working on optimizing our processes and organization. To streamline, save costs, and be able to achieve the best development at our newly acquired Finnish group Riikku, a decision has been made to restructure their operations and company structure. In Finland, Riikku Group Oy has restructured its organization into three business areas: new build, renovation and service. Their subsidiary Riikku Koti, which works in the renovation side and towards consumers, will be incorporated into the parent company Riikku Group Oy. Together with employees of Riikku Group Oy,

Invitation to Exel Composites' Q3 2024 financial results briefing on 31 October 2024

EXEL COMPOSITES PLC          INVESTOR NEWS       24 OCTOBER 2024 AT 9:00 EETExel Composites will publish its Business Review Q1-Q3 2024 on Thursday 31 October 2024 at approximately 9:00 EET. Investors, analysts and journalists are invited to participate in the financial results briefing at 12:30 EET on the same day. The briefing will be hosted by President and CEO Paul Sohlberg and CFO Mikko Rummukainen.   The briefing will be organized online. To participate in the event, please register in advance by sending an email to investor@exelcomposites.com by Wednesday 30 October 2024. A

Stable quarter with good profitability

"We leave behind us a stable quarter, with sales growth in all operating segments together with continued good profitability. The Group's total sales amounted to SEK 9,493 million, corresponding to a growth of 12 per cent. EBITA amounted to SEK 1,084 million, corresponding to an increase of 13 per cent, and the EBITA margin was 11.4 per cent (11.3). Organic sales increased by 3 per cent during the period. A good operating cash flow of SEK 1,231 million continues to support expansionary possibilities in the market," says CEO Christopher Norbye. Webcast and Telephone conference Q3 2024

Interim Report Q3: 1 Jan–30 Sept 2024

Continued weak market – several initiatives for the futureThird quarter highlights · Revenue increased by 1.0 per cent to MSEK 2,143 (2,122). Organic growth was -3.0 per cent. · Gross margin was 40.5 per cent (41.6). · Adjusted EBITA decreased to MSEK 137 (191), corresponding to an adjusted EBITA margin of 6.4 per cent (9.0). · Operating profit decreased to MSEK 115 (175) and the operating margin was 5.4 per cent (8.2). Operating profit was charged with items affecting comparability of MSEK -6 (0). · Profit amounted to MSEK 60 (113). · Earnings per share amounted to SEK

Attendo’s third quarter report 2024: IMPROVEMENT IN PERFORMANCE AND CUSTOMER SATISFACTION

Attendo continues to report good growth in both sales and profit in the third quarter of 2024. In Scandinavia, sales and profit increased mainly as a result of the acquisition of Team Olivia and continued good development in own nursing homes. In Finland, sales are also increasing and profit improved compared with the third quarter of 2023. Attendo also noted a clear increase in customer satisfaction in national user surveys in both Sweden and Finland.Comments from Martin Tivéus, Attendo president and CEO “We continue to show good growth in both sales and earnings in the third quarter.

Notice of Annual General Meeting of AcadeMedia AB (publ)

The shareholders of AcadeMedia AB (publ), reg, no. 556846-0231, with its registered office in Stockholm, are summoned to the Annual General Meeting on Thursday 28 November 2024 at 2 p.m. at AcadeMedia’s head office, Adolf Fredriks Kyrkogata 2, Stockholm. Registration starts at 1 p.m.   Timeline: Record Date                                                               20 November 2024 Last day to notify attendance                                                22 November 2024 Last day to re-register nominee-registered shares                          22 November 2024 Date of

AcadeMedia’s interim report, July 2024 – September 2024

First quarter (July – September 2024) · Net sales increased by 12,0 percent and amounted to SEK 3,842 million (3,430). Organic growth, including bolt-on acquisitions, was 6.0 percent. · Operating profit (EBIT) amounted to SEK 272 million (232). · Adjusted operating profit, adjusted for items affecting comparability and effects of IFRS 16, amounted to SEK 157 million (151). There were no items affecting comparability in the quarter (SEK -6 million). · Net profit for the period amounted to SEK 80 million (62). · Earnings per share was SEK 0.79 (0.59) after dilution. Adjusted

Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

Stockholm, October 24, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for Alzheimer's Disease Conference (CTAD) held in Madrid, Spain, and virtually from October 29 to November 1. Lars Lannfelt will be one of the keynote speakers at the conference. In addition, BioArctic’s partner Eisai present lecanemab data in two oral and one poster presentation at the meeting and three symposia will focus on lecanemab. Data shared will include the

News conference on Kojamo’s Interim Report for January–September 2024 on 7 November 2024

Kojamo plc Press Release, 24 October 2024 at 9:00 a.m. EESTNews conference on Kojamo’s Interim Report for January–September 2024 on 7 November 2024 Kojamo plc’s Interim Report for January–September 2024 will be published on Thursday, 7 November 2024 at approximately 8:00 a.m. EET. News conference and webcast Kojamo will hold a news conference for institutional investors, analysts and media on 7 November 2024 at 10:00 a.m. EET at its headquarters at Mannerheimintie 168A, Helsinki, Finland. The event will be hosted by Kojamo’s Interim CEO Erik Hjelt, and it will be held in English.

Careiums AB’s Nomination Committee for the 2025 Annual General Meeting

In accordance with the decision by Careium AB’s Annual General Meeting (AGM) on April 25, 2024, the chairman of the board, Maria Khorsand, has summoned the Nomination Committee.After consultation with the major shareholders of the company as per 30 September 2024, the committee consists of the following members: · Peter Lindell, Cidro Capital Förvaltning, appointed commitee Chairman, · Mark Shay, Accendo Capital · Richard Torgerson, Nordea Funds · Maria Khorsand, Chairman of the Board, adjunct member of the Nomination Committee The Nomination Committee will prepare

AcadeMedia publishes the Annual and Sustainability report for 2023/2024

AcadeMedia’s 2023/2024 Annual Report is now available on the corporate website, and as an attached pdf to this press release. The Sustainability report is located on pages 15-47.https://academedia.se/en/about-us/investors/reports-and-presentations/ With consideration to the environment, this Annual and Sustainability report is only published digitally. For more information, please contact:Hanna Clausén, IRTelephone: +46 70 587 97 67E-mail: hanna.clausen@academedia.se About AcadeMedia AcadeMedia creates opportunities for people to develop. The 21,000 employees at our 860

OKEA third quarter 2024 trading update

(Trondheim, 24 October 2024) OKEA ASA (OSE: OKEA) will publish its financial report for the third quarter of 2024 on Thursday 31 October at 06:00 (CEST). This trading update is provided to summarise production and sales volumes and related updates for the quarter.Third quarter 2024 production and sales   Unit Q3 2024 Q2 2024Total operating income MNOK 2,926 2,584Realised liquids price USD/boe 74.9 79.7Realised gas price USD/boe 68.9 65.7Net production

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024Third Quarter 2024 •         Total revenue increased 33 per cent, 39 per cent at constant exchange rates, (CER)1, to SEK 6,894 M (5,168) •         Haematology revenue increased 18 per cent at CER to SEK 4,000 M (3,484), mainly driven by strong sales of Doptelet[®] of SEK 1,039 M (650), sales of Aspaveli[®]/Empaveli[®] of SEK 270 M (169) and launch sales of Altuvoct[®] of SEK 129 M (—)  •         Immunology revenue increased 96 per cent at CER to SEK 2,583 M (1,400), driven by strong

Fractal Gaming Group Interim Report January-September 2024

Third quarter 2024•    Net sales amounted to SEK 156.6 million (189.9).•    Product profit amounted to SEK 59.1 million (79.3), with a product margin of 37.8% (41.8).•    EBITDA amounted to SEK 11.6 million (35.1), corresponding to an EBITDA margin of 7.4% (18.5).•    EBIT amounted to SEK 5.7 million (29.8), corresponding to an EBIT margin of 3.6% (15.7).•    Operating cash flow amounted to SEK 14.8 million (65.0).•    Interest-bearing net debt was SEK -29.8 million (-75.5).•    Earnings per share amounted to SEK 0.0 (0.8).•    No items affecting comparability for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top